Zacks Research Upgrades Check-Cap (NASDAQ:MBAI) to “Hold”

Check-Cap (NASDAQ:MBAI) was upgraded by Zacks Research to a “hold” rating in a note issued to investors on Tuesday, Zacks reports.

Several other research firms have also weighed in on MBAI. Northland Securities initiated coverage on shares of Check-Cap in a report on Monday. They issued an “outperform” rating and a $10.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Check-Cap in a report on Tuesday, July 21st. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $10.00.

Check-Cap Stock Performance

Shares of NASDAQ MBAI opened at $3.54 on Tuesday. The stock has a market cap of $4.89 million, a PE ratio of -0.25 and a beta of 0.67. The business has a fifty day moving average of $7.04 and a two-hundred day moving average of $9.36. Check-Cap has a 52-week low of $3.34 and a 52-week high of $27.44.

Check-Cap Company Profile

Check-Cap Ltd. was an Israel-based medical diagnostics company focused on developing noninvasive technologies for colorectal cancer screening. Its lead product, C-Scan, was an ingestible, capsule-based imaging system designed to examine the colon for polyps and other abnormalities without requiring the extensive bowel preparation typically associated with conventional colonoscopy.

The C-Scan system was intended to combine a disposable capsule with an external tracking and data-collection system, allowing physicians to review images of the gastrointestinal tract after the capsule passed through the body.